• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Recursion Pharmaceuticals Inc.

    3/6/25 11:55:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001856369
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    RECURSION PHARMACEUTICALS, INC.
    SEC File Number
    001-40323
    Address of Issuer
    41S RIO GRANDE STREET
    SALT LAKE CITY
    UTAH
    84101
    Phone
    (385) 269-0203
    Name of Person for Whose Account the Securities are To Be Sold
    Gibson Christopher
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    20000127400.0039507209403/06/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A09/01/2016Founders SharesIssuerCheckbox not checked2000009/01/2016Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Christopher C. Gibson
    41 S Rio Grande Street
    Salt Lake City � UT � 84101
    Class A01/08/202520000146200.00
    Christopher C. Gibson
    41 S Rio Grande Street
    Salt Lake City � UT � 84101
    Class A01/10/202520000141000.00
    Christopher C. Gibson
    41 S Rio Grande Street
    Salt Lake City � UT � 84101
    Class A02/05/202520000153600.00
    Christopher C. Gibson
    41 S Rio Grande Street
    Salt Lake City � UT � 84101
    Class A02/06/202520000162400.00
    Christopher C. Gibson
    41 S Rio Grande Street
    Salt Lake City � UT � 84101
    Class A03/05/202520000131600.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/06/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    12/27/2023

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Christopher C. Gibson.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    9/21/2021$37.00Buy
    Berenberg
    8/16/2021$33.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 4:57:06 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 10:34:18 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/4/24 4:16:21 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    SEC Filings

    See more

    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 8-K filed by Recursion Pharmaceuticals Inc.

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/9/25 5:27:47 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B7 filed by Recursion Pharmaceuticals Inc.

      424B7 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/9/25 5:26:22 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Recursion Pharmaceuticals Inc.

      S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:07:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Participate in Upcoming Investor Conferences

      Salt Lake City, May 30, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference — Thursday, June 5, 2025 Goldman Sachs 46th Annual Global Healthcare Conference — Tuesday, June 10, 2025 TDCowen 4th Annual Tools/Dx Revolution Conference — Monday, June 23, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to

      5/30/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Participate in Upcoming Investor Conferences

      Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.  About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the

      5/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

      Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful synergies and streamlined operations while maintaining capabilities, resulting in cash runway until mid 2027 SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a le

      5/5/25 6:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

      5/22/23 7:50:41 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on Recursion Pharmaceuticals with a new price target

      Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00

      3/16/23 9:18:01 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • KeyBanc Capital Markets initiated coverage on Recursion Pharmaceuticals with a new price target

      KeyBanc Capital Markets initiated coverage of Recursion Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      9/16/22 7:27:04 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief R&D Commercial Officer Khan Najat covered exercise/tax liability with 3,796 shares, decreasing direct ownership by 0.53% to 708,585 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      5/19/25 4:44:24 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Taylor Ben R covered exercise/tax liability with 11,908 shares, decreasing direct ownership by 1% to 830,191 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      5/19/25 4:44:12 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Gibson Christopher covered exercise/tax liability with 36,197 shares, decreasing direct ownership by 3% to 1,081,253 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      5/19/25 4:44:03 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

      Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

      3/18/25 8:00:00 AM ET
      $DVAX
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Altitude Lab Startups Raise $154M in Capital

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta

      2/18/25 11:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

      Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/Michael Secora, PhD, Chief Cor

      1/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RXRX
    Financials

    Live finance-specific insights

    See more
    • Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

      Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo

      4/28/25 8:27:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

      Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit

      2/24/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

      REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatmentPlans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --

      12/9/24 6:00:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care